CN1195546C - 结合cd154的单克隆抗体抑制产生胰岛素的组织移植物的排斥的用途 - Google Patents

结合cd154的单克隆抗体抑制产生胰岛素的组织移植物的排斥的用途 Download PDF

Info

Publication number
CN1195546C
CN1195546C CNB988064413A CN98806441A CN1195546C CN 1195546 C CN1195546 C CN 1195546C CN B988064413 A CNB988064413 A CN B988064413A CN 98806441 A CN98806441 A CN 98806441A CN 1195546 C CN1195546 C CN 1195546C
Authority
CN
China
Prior art keywords
insulin
tissue
cell
cells
islet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988064413A
Other languages
English (en)
Chinese (zh)
Other versions
CN1261286A (zh
Inventor
N·S·凯尼昂
C·瑞科迪
D·W·索马斯
L·布克利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Biogen MA Inc
Original Assignee
Biogen Inc
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, University of Miami filed Critical Biogen Inc
Publication of CN1261286A publication Critical patent/CN1261286A/zh
Application granted granted Critical
Publication of CN1195546C publication Critical patent/CN1195546C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Steroid Compounds (AREA)
  • External Artificial Organs (AREA)
CNB988064413A 1997-06-20 1998-06-19 结合cd154的单克隆抗体抑制产生胰岛素的组织移植物的排斥的用途 Expired - Fee Related CN1195546C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5026797P 1997-06-20 1997-06-20
US60/050,267 1997-06-20
US7726598P 1998-03-09 1998-03-09
US60/077,265 1998-03-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2005100079419A Division CN1651919A (zh) 1997-06-20 1998-06-19 结合cd154的单克隆抗体抑制产生胰岛素的组织移植物的排斥的用途

Publications (2)

Publication Number Publication Date
CN1261286A CN1261286A (zh) 2000-07-26
CN1195546C true CN1195546C (zh) 2005-04-06

Family

ID=26728084

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB988064413A Expired - Fee Related CN1195546C (zh) 1997-06-20 1998-06-19 结合cd154的单克隆抗体抑制产生胰岛素的组织移植物的排斥的用途
CNA2005100079419A Pending CN1651919A (zh) 1997-06-20 1998-06-19 结合cd154的单克隆抗体抑制产生胰岛素的组织移植物的排斥的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2005100079419A Pending CN1651919A (zh) 1997-06-20 1998-06-19 结合cd154的单克隆抗体抑制产生胰岛素的组织移植物的排斥的用途

Country Status (21)

Country Link
US (2) US20030072754A1 (OSRAM)
EP (1) EP1051191B1 (OSRAM)
JP (1) JP2002506446A (OSRAM)
KR (1) KR100634847B1 (OSRAM)
CN (2) CN1195546C (OSRAM)
AT (1) ATE339966T1 (OSRAM)
AU (1) AU730763B2 (OSRAM)
BG (1) BG64976B1 (OSRAM)
BR (1) BR9810620A (OSRAM)
CA (1) CA2294154A1 (OSRAM)
DE (1) DE69835965T2 (OSRAM)
EA (1) EA002550B1 (OSRAM)
EE (1) EE9900588A (OSRAM)
HU (1) HUP0003160A3 (OSRAM)
IL (1) IL133303A0 (OSRAM)
IS (1) IS5273A (OSRAM)
NO (1) NO996275L (OSRAM)
NZ (1) NZ502052A (OSRAM)
SK (1) SK180299A3 (OSRAM)
TR (1) TR199903142T2 (OSRAM)
WO (1) WO1998058669A2 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045958A1 (en) * 1998-03-09 1999-09-16 Biogen, Inc. Cd154 blockade therapy for modulation of immune responses to implanted devices
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
AU2001275186A1 (en) * 2000-06-02 2001-12-17 Nicole Kirchhof Immunotherapeutic method to prevent islet cell rejection
EP1294391B1 (en) * 2000-06-09 2012-08-15 Bristol-Myers Squibb Company Combination of agents for inhibiting transplant rejection
DE602004029252D1 (de) * 2003-06-13 2010-11-04 Biogen Idec Inc Aglycosyl-anti-cd154 (cd40-ligand) antikörper und deren verwendungen
CZ200755A3 (cs) 2004-07-26 2007-04-11 Biogen Idec Ma Inc. Peptidy protilátek anti-CD154
WO2006054305A2 (en) * 2004-11-22 2006-05-26 Ramot At Tel Aviv University Ltd. Populations of expanded and re-differentiated adult islet beta cells capable of producing insulin and methods of generating same
US20070087029A1 (en) * 2005-10-14 2007-04-19 Pakala Syamasundar V Localized delivery to the lymphatic system
US8372399B2 (en) 2006-08-31 2013-02-12 Cardiac Pacemakers, Inc. Bispecific antibodies and agents to enhance stem cell homing
US8636995B2 (en) 2006-08-31 2014-01-28 Cardiac Pacemakers, Inc. Methods and devices to regulate stem cell homing
EP2396348B1 (en) * 2009-02-10 2015-04-08 The Trustees of Columbia University in the City of New York Compositions comprising hla-e for use in methods for inducing transplantation tolerance
WO2011146395A2 (en) 2010-05-17 2011-11-24 The Board Of Trustees Of The Leland Stanford Junior University Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10147463B2 (en) 2014-12-10 2018-12-04 Nxp Usa, Inc. Video processing unit and method of buffering a source video stream
US9512229B2 (en) * 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
KR101810778B1 (ko) * 2015-06-23 2017-12-20 서울대학교산학협력단 Cd154 결합 폴리펩타이드 및 그 용도
US10986309B2 (en) 2015-06-30 2021-04-20 Nxp Usa, Inc. Video buffering and frame rate doubling device and method
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227298A (en) * 1990-08-17 1993-07-13 The Trustees Of Columbia University In The City Of New York Method for microencapuslation of cells or tissue
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
AU710998B2 (en) * 1996-03-20 1999-10-07 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4 /CD28/B7 pathways and compositions for use therewith

Also Published As

Publication number Publication date
BR9810620A (pt) 2000-10-03
US20030072754A1 (en) 2003-04-17
AU7983098A (en) 1999-01-04
NZ502052A (en) 2001-01-26
EE9900588A (et) 2000-08-15
DE69835965T2 (de) 2007-06-14
JP2002506446A (ja) 2002-02-26
CA2294154A1 (en) 1998-12-30
HUP0003160A3 (en) 2002-09-30
TR199903142T2 (xx) 2000-09-21
KR100634847B1 (ko) 2006-10-17
SK180299A3 (en) 2000-06-12
HUP0003160A2 (hu) 2001-01-29
WO1998058669A3 (en) 1999-04-29
EP1051191B1 (en) 2006-09-20
HK1033548A1 (en) 2001-09-07
DE69835965D1 (de) 2006-11-02
EA002550B1 (ru) 2002-06-27
US20070292440A1 (en) 2007-12-20
BG104091A (en) 2000-10-31
CN1651919A (zh) 2005-08-10
CN1261286A (zh) 2000-07-26
WO1998058669A2 (en) 1998-12-30
AU730763B2 (en) 2001-03-15
EP1051191A2 (en) 2000-11-15
IL133303A0 (en) 2001-04-30
EA200000058A1 (ru) 2000-08-28
KR20010013965A (ko) 2001-02-26
BG64976B1 (bg) 2006-11-30
NO996275D0 (no) 1999-12-17
NO996275L (no) 2000-02-21
ATE339966T1 (de) 2006-10-15
IS5273A (is) 1999-11-26

Similar Documents

Publication Publication Date Title
CN1202864C (zh) Cd40:cd154结合阻断物在制备预防逆适应性免疫应答,特别是移植物排斥反应的药物中的用途
EP1051191B1 (en) CD154 BLOCKADE THERAPY FOR PANCREATIC ISLET TISSUE TRANSPLANTATION in primates
JP2002502824A (ja) 同種移植における補刺激遮断および混合キメラ現象
US20030170239A1 (en) Immunotherapeutic method to prevent islet cell rejection
WO2005021734A2 (en) Generation of hematopoietic chimerism and induction of central tolerance
EP1754490A2 (en) CD 154 blockage therapy for pancreatic islet tissue transplantation in primates
HK1033548B (en) Cd154 blockade therapy for pancreatic islet tissue transplantation in primates
CN1736483A (zh) 应用cd40：cd154结合阻断物预防反适应性免疫应答,特别是移植物排斥反应
WO1999045958A1 (en) Cd154 blockade therapy for modulation of immune responses to implanted devices
CZ461699A3 (cs) Použití činidla rušícího vazbu CD40:CD154 pro přípravu léku k zabránění odhojení štěpu tkáně tvořící inzulín
MXPA99011740A (en) Cd154 blockade therapy for pancreatic islet tissue transplantation
PL191122B1 (pl) Zastosowania przerywacza wiązania CD40:CD154
JP2002521042A (ja) 同種異系および異種のＴ細胞のｇｐ３９アンタゴニストによる生体外処置
JPH09500364A (ja) 異種移植片の胸腺
CZ403599A3 (cs) Použití činidla rušícího vazbu CD40:CD154 pro výrobu léku k inhibici odhojení tkáňového štěpu a přípravek obsahující činidlo rušící vazbu CD40:CD154
MXPA99010571A (en) Use of a cd40:cd154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: BIOGEN IDEC MASSACHUSETTS, CO.,LTD.; MIAMI UNIVERS

Free format text: FORMER NAME OR ADDRESS: BIOGEN, INC.; MIAMI UNIVERSITY

Owner name: BIOGEN IDEC MASSACHUSETTS CORPORATION; MIAMI UNIVE

Free format text: FORMER NAME OR ADDRESS: BIOGEN IDEC MASSACHUSETTS, CO.,LTD.; MIAMI UNIVERSITY

CP01 Change in the name or title of a patent holder

Address after: Massachusetts USA

Co-patentee after: University OF MIAMI

Patentee after: Biogen Idec MA Inc.

Address before: Massachusetts USA

Co-patentee before: University OF MIAMI

Patentee before: Biogen, Inc.

CP03 Change of name, title or address

Address after: Massachusetts USA

Co-patentee after: University OF MIAMI

Patentee after: Biogen Idec MA Inc.

Address before: Massachusetts USA

Co-patentee before: University OF MIAMI

Patentee before: Biogen IDEC Ma Inc.

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee